FindTrial
Sign In

comparison of two drugs for better treatment of covid-19 related lung problems

Nintedanib Vs Pirfenidone in management of Covid19 related lung abnormality

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/12/029814
Enrollment
30
Registered
2020-12-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: NINTEDANIB: 150 MG CAPSULE TO BE GIVEN BD FOR A DURATION OF 12 WEEKS MAXIMUM. Control Intervention1: tab pirfenidone 600 mg tid: 600 MG TAB TO BE GIVEN TID FOR A DURATION OF 12 WEEKS MA

Sponsors

PRATIMA SINGH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All cases of covid 19 pneumonia who were diagnosed as COVID positive >=15 days back or antibody positive and continue to be breathless symptomatically, have SPo2 =10 and CORADS-4/5/6

Exclusion criteria

Exclusion criteria: -Patients having other interstitial lung diseases. - Patient having CKD or creatinine clearance -Not fulfilling the criteria for study -Not giving consent for study.

Design outcomes

Primary

MeasureTime frame
Improvement in CT-severity score Improvement in Arterial Blood Gas. Timepoint: 0, 6weeks, 12weeks—

Secondary

MeasureTime frame
Improvement in 6Minute Walk Distance.Timepoint: 6 weeks, 12 weeks—

Countries

India

Contacts

Public ContactDeepak Sahoo

KALINGA INSTITUTE OF MEDICAL SCIENCES

drppratima@gmail.com8895613285

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026